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Abstract
Background: The unique S28 family of proteases is comprised of the carboxypeptidase PRCP and the aminopeptidase 
DPP7. The structural basis of the different substrate specificities of the two enzymes is not understood nor has the 
structure of the S28 fold been described.
Results: The experimentally phased 2.8 Å crystal structure is presented for human PRCP. PRCP contains an α/β 
hydrolase domain harboring the catalytic Asp-His-Ser triad and a novel helical structural domain that caps the active 
site. Structural comparisons with prolylendopeptidase and DPP4 identify the S1 proline binding site of PRCP. A 
structure-based alignment with the previously undescribed structure of DPP7 illuminates the mechanism of 
orthogonal substrate specificity of PRCP and DPP7. PRCP has an extended active-site cleft that can accommodate 
proline substrates with multiple N-terminal residues. In contrast, the substrate binding groove of DPP7 is occluded by a 
short amino-acid insertion unique to DPP7 that creates a truncated active site selective for dipeptidyl proteolysis of N-
terminal substrates.
Conclusion: The results define the structure of the S28 family of proteases, provide the structural basis of PRCP and 
DPP7 substrate specificity and enable the rational design of selective PRCP modulators.
Background
Proteases are an important class of enzymes involved in a
diverse range of physiological processes. The modulation
of proteolytic activity is an established means of thera-
peutic intervention with currently marketed products for
afflictions as diverse as type 2 diabetes, hypertension and
viral infections. The human protease tree is comprised of
at least 676 diverse proteins that have been systematically
organized into clans and families based on similarity in
sequence, structure, and function [1]. Although the struc-
tural basis of catalytic mechanism, substrate specificity
and rational drug design has been identified for numer-
ous protease families, there has been no structural
description of the S28 family of proteases that form a dis-
tinct branch of the serine carboxypeptidase clan.
The S28 family of peptidases consists of two enzymes,
PRCP and DPP7. DPP7 is also called dipeptidyl peptidase
2 and quiescent cell proline dipeptidase [2-4]. PRCP is a
lysosomal, serine carboxypeptidase that cleaves hydro-
phobic C-terminal amino acids adjacent to proline [5,6].
In contrast, DPP7 is a serine dipeptidyl aminopeptidase
that cleaves N-terminal amino acids adjacent to proline
and is localized to intracellular vesicles [3].
Human PRCP and human DPP7 share 39.6% sequence
identity and 55.4% sequence similarity. At the sequence
level, the two enzymes are unrelated to other proteases;
the next closest human homologues are PEP (8.4%
sequence identity and 13.9% sequence similarity) and
DPP4 (6.5% sequence identity and 11.2% sequence simi-
larity). The S28 proteases PRCP and DPP7 are therefore
unique within the protease superfamily.
PRCP was originally discovered as an angiotensinase
[7] and has since been implicated in vasodilatory, proin-
flammatory, and metabolic pathways [6,8,9]. For example,
angiotensin II, III and prekallikrein are all inactivated by
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PRCP, implicating a role for the enzyme in hypertension,
tissue proliferation and smooth muscle growth. PRCP is
also reported to inactivate α-melanocyte-stimulating
hormone, a neuropeptide that plays a role in regulating
appetite [10]. DPP7 has been implicated in apoptosis in
quiescent lymphocytes [3].
Here we report the crystal structure of human PRCP.
The enzyme consists of an α/β hydrolase domain that
contains a unique structural domain insertion that caps
the active site. Comparison with the recently released
coordinates of DPP7 illuminates the structural basis for
the different substrate specificities of PRCP and DPP7.
The results lay the foundation for understanding the
structural basis of PRCP activity and for the structure-
guided discovery of PRCP modulators for target valida-
tion and disease modification.
Results and Discussion
The structure of PRCP
The crystal structure of human PRCP was determined
using MIRAS phasing techniques at 2.8 Å resolution by
analyzing native, mercury and platinum-derivatized crys-
tals (Table 1). Interpretation of heavy-atom positions and
resultant electron-density maps show that the asymmet-
ric unit contains one molecule of PRCP with an unusually
high solvent content of 82%. Although the derivative data
sets provided modest amounts of phase information, a
very high-quality experimental electron density map was
obtained. These results reflect the high redundancy of the
data and high solvent content of the crystals.
The experimental maps allowed nearly the entire struc-
ture of PRCP to be modeled and subsequently refined.
The final refined model consists of residues 46-348 and
353-491, five N-linked glycans, and four disulfide bridges
(residues 215-372, 233-310, 264-343 and 364-394). The
final R and Rfree values are 21.8% and 24.1%, respectively.
Geometry and stereochemistry are good with 95% of the
residues in the most favored region of the Ramachandran
plot and an overall MolProbity score of 88%. One region
of unexplained tubular electron density is observed in the
S1' active site area that may correspond to a structurally
heterogeneous population of bound polymer (e.g., poly-
ethylene glycol) and a second peak of unexplained elec-
tron density is observed near the putative proline S1
binding site.
The overall architecture of PRCP consists of two main
structural entities: an α/β hydrolase domain and a novel
SKS domain (Figures 1A and 1B). The α/β hydrolase
domain is constructed from two non-contiguous
stretches of PRCP (residues 46-204 and 405-491).
Table 1: Structure determination statistics.
Native EMTS K2PtCl4
Resolution (Å) 2.80 2.8 3.0
Space group R32 R32 R32
Unit-cell dimensions (Å) a = b = 181.14
c = 240.13
a = b = 179.76
c = 240.90
a = b = 181.27
c = 240.02
Completeness (%) 100 (100) 99.9 (100) 95.8 (69.6)
Redundancy 10.9 10.2 5.1
Rsym (%) 9.8 (59.4) 8.4 (60.9) 11.5 (38.3)
Rmerge(%) -2 4 . 2 1 8 . 3
Heavy atom sites - 20 13
Isomorphous phasing power - 1.25/1.22 1.28/1.36
Anomalous phasing power - 0.482 0.335
Isomorphous Rcullis - 0.784/0.722 0.717/0.595
Anomalous Rcullis - 0.656 0.947
Overall FOM 0.344/0.426
Resolution (Å) 50.0-2.79
Rf (%) 21.8
Rfree (%) 24.1
Protein atoms 3529
Water molecules 93
Values in parentheses are for the highest resolution bin.Soisson et al. BMC Structural Biology 2010, 10:16
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A l t h o u g h  a  n u m b e r  o f  β - s h e e t  t o p o l o g i e s  h a v e  b e e n
described for the α/β hydrolase fold [11], the β-sheet
topology of PRCP is identical to the prototypical α/β
hydrolase fold [12].
The unique insertion in the PRCP hydrolase domain
occurs between strand 6 and helix D and spans residues
194-398. The first part of the insertion (residues 194-334)
consists of five helices packed into a novel helical bundle
(the SKS domain) that caps the active site (Figure 1B). A
DALI search to identify structures containing similar
helical bundles to the SKS domain did not identify pro-
teins with similar folds (Z scores < 3.3), suggesting that
the SKS domain is a novel structural motif.
Four residues following the SKS domain are likely dis-
ordered as evidenced by a lack of electron density (resi-
dues 349-352). The region is followed by a pair of helices
(M and N) that are linked by two long, irregular, loosely
packed strands that form a concave surface at one
entrance to the active site. The irregular strands and the
M and N helices appear to provide additional stabilizing
interactions between the SKS and hydrolase domains and
form part of the substrate binding surface (Figure 1B).
Previously reported mass-spectrometry results are con-
sistent with the CHO-expressed PRCP protein containing
about 9 kDa of glycan [13]. Sequence analysis suggests
that there are six possible N-glycosylation sites at aspar-
agines 47, 101, 317, 336, 345 and 415 that correspond to
the canonical glycosylation sequence Asn-Xaa-Ser/Thr
[14]. Asn 47 is not glycosylated in the structure, in accord
with mass-spectrometric mapping of glycan sites [13].
Clear evidence of covalently attached and ordered sac-
charide is observed at the other five canonical glycosyla-
tion sites (Figure 1B). The presence of extensive
glycosylation is likely a contributing factor to the high
solvent content of the crystals.
A crystallographic dimerization interface is seen that
involves the hydrolase domain (Figure 2). The dimer
interface is formed through packing interactions across a
two-fold crystallographic symmetry axis present in the
crystal, and buries approximately 3600 Å2 of surface area
on the combined molecules of PRCP. This observation is
consistent with previous gel-filtration and dynamic-light
scattering results suggesting that PRCP is a dimer in solu-
tion [6,13,15].
The active site of PRCP
The catalytic triad consisting of Ser 179, Asp 430 and His
455 (Figure 3A) can be identified based on structural sim-
ilarity with other hydrolases [12]. Ser 179 is located on a
sharp turn between strand 5 and helix C, Asp 430 is
located between strand 7 and helix E, and His 455 is
located on the loop between strand 8 and helix F. Ser 179,
Figure 1 The structure of PRCP. (A) Schematic diagram of the secondary structure of PRCP. The canonical α/β hydrolase fold is shown in blue and 
cyan, the SKS domain in magenta, and the M and N helices of the hydrolase insert domain in yellow. (B) Ribbon diagram of tertiary structure of PRCP. 
The Asp-His-Ser catalytic triad is shown in red. Glycans are shown in green.
A                                        BSoisson et al. BMC Structural Biology 2010, 10:16
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Asp 430 and His 455 are spatially oriented in the same
catalytic triad arrangement seen in other serine α/β
hydrolases such as DPP4 (Figure 3B). The active site is
located on one face of the hydrolase domain and is
capped by the SKS domain. The putative oxyanion hole is
formed by the backbone amide nitrogen atoms of Tyr 180
and Gly 181. The side chain of Asn 92 is also positioned
in close proximity to the putative oxyanion hole and may
play a role in stabilizing the negatively charged tetrahe-
d r a l  i n t e r m e d i a t e  f o r m e d  d u r i n g  c a t a l y s i s .  O t h e r  p r o -
teases containing the hydrolase fold adopt a similar
arrangement of the catalytic triad and oxyanion hole,
although the nature of the capping domain varies. For
example, DPP4 and PEP are capped with a β-propeller
domain [16-18] and human protective protein is capped
with a helical bundle unrelated to the SKS domain [19].
An unanticipated feature of the PRCP active site is an
apparent charge-relay system that links the catalytic histi-
dine (His 455) with His 456 and Arg 460 (Figure 3A). The
arrangement of side chains places the imidazole nitrogen
atoms of His 455 and His 456 within 3.0-3.5 Å of the cata-
lytic serine. The guanidinium group of Arg 460 is in
hydrogen bond distance (2.8 Å) of the imidazole ring of
His 456. It seems likely that this unique arrangement of
residues plays a role in the catalytic mechanism of PRCP.
Furthermore, it is possible that the presence of the for-
mally charged Arg 460 in close contact with the tandem
histidines could alter the pKa of His 455 contributing to
the acidic pH optimum (5.5) for both PRCP and DPP7
[6,20,21].
The tandem His-His arrangement is not seen in other
serine α/β hydrolases with the exception of the lipases.
For example, pancreatic lipase [22], contains a second
histidine residue located spatially adjacent to the catalytic
histidine in the active site (Figure 3B). In the lipases, the
equivalent second His residue is contributed to the active
site by a different structural element of the α/β hydrolase
fold, and may therefore represent a convergent evolution
of the S28 protease family and the lipases. The structural
conservation underscores the potential importance of the
histidine pair in catalysis.
Recognition of Pro-X peptide substrates by PRCP
PRCP cleaves carboxy-terminal residues of peptide sub-
strates that contain a penultimate proline. This is exem-
plified by angiotensin II, the first substrate identified for
PRCP (NDRVYIHPF) [23] and bradykinin (RPPGFSPF)
[8]. In contrast, peptides lacking the penultimate Pro,
such as angiotensin I (DRVYIHPFHL), are not substrates
for the enzyme [21].
Examination of the active site for potential substrate
recognition pockets reveals the presence of a hydropho-
bic pocket adjacent to the catalytic serine. This pocket is
formed primarily by Met 183, Met 369, Trp 432 and Trp
459 (Figure 4). The proline S1 binding site of other pro-
line peptidases is illustrated by PEP and DPP4, which
share limited sequence similarity to PRCP and to each
other (8% over the hydrolase domain). The structure of
substrate-bound PEP [24] shows that the Pro residue of
the cleaved substrate (EFSP) is located in a hydrophobic
pocket formed by Trp 595 and Phe 476 that is adjacent to
the catalytic serine (Figure 5A). Similarly, the structure of
DPP4 with a bound peptide substrate shows that the sub-
strate proline is recognized in a pocket formed by Tyr 662
and Tyr 666 (Figure 5B). Structural alignments strongly
suggest that the hydrophobic pocket in PRCP, formed by
Trp 432, Trp 459, Met 183 and Met 369 is functionally
equivalent to the S1 binding sites of PEP and DPP4.
Substrate specificity of the S28 protease family
PRCP shares 39.6% sequence identity with DPP7 (Figure
6). The crystal structure of DPP7 was recently deposited
with the Protein Data Bank by the Structural Genomics
Figure 2 The PRCP Dimer. The crystallographic dimer of PRCP with 
monomer subunits shown in green and blue.Soisson et al. BMC Structural Biology 2010, 10:16
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Consortium (PDB code: 3JYH), although the structure is
not yet described in print. Essentially all of the structural
features observed for PRCP, including the α/β hydrolase
domain, the novel SKS domain, the dimerization inter-
face, the unusual Arg-His-His interaction in the active
site, and the Pro S1 binding site are preserved between
the two enzymes (Figures 7A-B). The Cα r.m.s.d. for the
aligned structures is 1.20 Å. The structural description
presented here for PRCP therefore defines the architec-
ture of the S28 protease family fold.
A striking difference between PRCP and DPP7 is a
structural insertion present only in DPP7 spanning resi-
dues 329-340 (Figures 6 and 7A). This short insertion
sequence adopts a hairpin structure that is stabilized by a
disulfide bridge between Cys 332 and Cys 338. The pep-
tide substrates of DPP7 and PRCP must occupy the two
enzymes in the same orientation based on the conserved
architectures of the catalytic triad and the S1 Pro binding
site. The structural insertion of DPP7 truncates the
active-site cleft of DPP7 (Figure 8) and explains the differ-
ent substrate specificities of the two enzymes. The bind-
ing of known substrates by PRCP that are cleaved at the
C-terminus requires access to the long substrate binding
groove of PRCP. In contrast, the DPP7-specific structural
insertion creates a blocked substrate binding site that can
only accommodate short, dipeptidyl extensions at the N-
terminus of potential substrates. This represents a
remarkably simple evolutionary adaptation to impart the
C- and N-terminal substrate specificities of PRCP and
DPP7 within a conserved active-site architecture.
The DPP7-specific insertion may also play an impor-
tant role in substrate binding. For the aminopeptidase
DPP4, substrate recognition involves coordination of the
Figure 3 The active site of PRCP. (A) The active site of PRCP. The Asp-His-Ser catalytic triad is shown in salmon. Additional active site side chain fea-
tures discussed in the text are colored according to structural element as in Figure 1. (B) Structural alignment of PRCP active site (blue), DPP4 (orange), 
and human pancreatic lipase (yellow) aligned on the catalytic histidine. PRCP residues are labeled.
Figure 4 The hydrophobic substrate-binding pocket of PRCP. The 
putative proline-binding pocket is formed by Trp 432 and Trp 359 
based on structural identity with other prolyl peptidases and the spa-
tial alignment with the Ser 179-His 455-Asp 430 catalytic triad.Soisson et al. BMC Structural Biology 2010, 10:16
http://www.biomedcentral.com/1472-6807/10/16
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N-terminal amine of the substrate by Glu 206 of DPP4
(Figure 5B) [17,18]. The importance of this interaction in
DPP4 is illustrated by the observations that the mutation
of Glu 206 in DPP4 abolishes enzymatic activity [25] and
that N-terminal acetylation of DPP4 substrates protects
against DPP4 proteolysis [26]. The insertion loop of
DPP7 also contains an acidic residue, Asp 334, which
could function to coordinate with the N-terminus of the
substrate in an analogous fashion to DPP4 (Figure 7B).
Conclusions
The structure of the human carboxypeptidase PRCP pre-
sented here provides the first structural description of the
S28 family of proteases. These proteases consist of a con-
served α/β hydrolase domain and a novel structural
domain that caps the active site. Comparison with the
previously undescribed structure of the aminopeptidase
DPP7 reveals that a short insertion sequence in DPP7
sterically occludes access to the substrate binding groove
to provide a simple evolutionary adaptation to change
substrate specificity. These structural results provide the
basis for rational design of selective PRCP regulators for
the modulation of cardiovascular and metabolic diseases.
Methods
Crystallization
Human PRCP was expressed, purified and crystallized as
described previously [13]. Briefly, glycosylated PRCP was
expressed as a secreted protein in CHO cells and purified
using a combination of Ni-affinity, heparin and gel filtra-
tion chromatography. Crystals were obtained in 1.8 M
ammonium sulfate, 0.1 M HEPES, pH 7.5, and 1-2% PEG
400 [13].
Structure determination
The structure of PRCP was determined using MIRAS
techniques (Table 1). Two heavy-atom derivatives were
prepared by soaking native PRCP crystals in stabilizing
solutions containing 5 mM ethyl mercurithiosalicylate or
2.5 mM K2PtCl4 for 2 or 10 days, respectively. Data were
collected at the Advanced Light Source beamline 5.0.2 by
Reciprocal Space Consulting. Diffraction images were
Figure 5 Identification of the proline recognition site. (A) Structur-
al alignment of PRCP (blue) with porcine PEP (yellow) in complex with 
the peptide substrate EFSP (PDB code: 1UOQ) in light blue. Residues 
discussed in the text are shown as sticks and labeled. (B) Structural 
alignment of PRCP (blue) with human DPP4 (orange) in complex with 
the peptide substrate YPSK (PDB code: 1R9N) in pink.
Figure 6 Structure-based sequence alignment of DPP7 and PRCP. 
Active site residues are marked in bold, underlined type. The DPP7-
specific structural insertion is in red. The four disordered residues not 
modeled in the PRCP structure are italicized.
PrCP  46  KNYSVLYFQ QKVDHFGFN- T-VKTFNQRY LVADKYWKKN GGSILFYTGN EGDIIWFCNNT
DPP7  28 DPGFQERFFQ QRLDHFNFER FGNKTFPQRF LVSDRFWVR- GEGPIFYTGN EGDVWAFANNS
PrCP 104 GFMWDVAEEL KAMLVFAEHR YYGESLPFGD NSFKDSRHLN FLTSEQALAD FAELIKHLKRT
DPP7  89 AFVAELAAER GALLVFAEHR YYGKSLPFGA QSTQG--THE LLTVEQALAD FAELLRALRRD
PrCP 165 IPGAENQPVI AIGGSYGGML AAWFRMKYPH MVVGALAASA PIWQFEDLVP CGVFMKIVTTD
DPP7 149 L-GAQDAPAI AFGGSYGGML SAYLR-KYPH LVAGALAASA PVLAVAGLGD SNQFFRDVTAD
PrCP 226 FRKSGPHCSE SIHRSWDAIN RLSNTGSGLQ WLTGALHLCS PLTSQ-DIQH LKDWISETWVN
DPP7 209 FEGQSPKCTQ GV-REFRQIK DLFLQGA-YD TVRWEFGTCQ PLSDEKDLTQ LFMFARNAFTV
PrCP 286 LAMVDYPYAS NFLQPLPAWP IKVVCQYLKN PNVSDSLLLQ NIFQALNVYY NYSGQVKCLNI
DPP7 269 LAMM-YPYPT DFLGPLPANP VKVGCDRL-- --LSEAQRIT GLRALAGLVY NASGSEHCDIY
PrCP 348 SETATS---- ----SLGTLG WSYQACTEVV MPFCTNGVDD MFEPHSWNLK ELSDDCFQQWG
DPP7 327 RLYHSCADPT GCGTGPDARA WDYQACTEIN LTFASNNVTD MF-PDLPTDE LRQRYCLDTWG
PrCP 400 VRPRPSWITT MYGGKNISSH TNIVFSNGEL DPWSGGGVTK DITDTLVAVT ISEGAHHLDLR
DPP7 388 VWPRPDWLLT SFWGGDLRAA SNIIFSNGNL DPWAGG-IRR NLSASVIAVT IQGGAHHLDLR
PrCP 461 TKNALDPMSV LLARSLEVRH MKNWIRDFYD SAGKQH
DPP7 449 ASHPEDPASV VEARKLEATI IGEWKAARRE QQPALRGGPRLSLSoisson et al. BMC Structural Biology 2010, 10:16
http://www.biomedcentral.com/1472-6807/10/16
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integrated using XDS [27] and reduced using SCALA
[28] as implemented in autoPROC (Global Phasing Lim-
ited, Cambridge, United Kingdom). Data sets were scaled
together using SCALEIT [29], and heavy atom sites iden-
tified with SHELXD [30]. These heavy atom sites were
used to seed runs of autoSHARP [31], combining native,
mercury, and platinum data sets, to generate initial
MIRAS phases and density-modified electron density
maps. An initial model of PRCP was built into the 2.8 Å
autoSHARP maps using Coot [32], and refined against
the native data set at 2.8 Å using iterative rounds of auto-
BUSTER [33] refinement and manual rebuilding. Mol-
Probity was used to evaluate the final refined model [34].
Figures were prepared with PyMOL [35]. Buried sur-
face-area calculations were performed using AREAIMOL
Figure 7 Structural comparison of DPP7 and PRCP. (A) Structural 
alignment of PRCP (blue) and DPP7 (yellow) and the sequence inser-
tion of DPP7 that occludes the active-site cleft (red). (B) Enlarged view 
of site region with DPP7-specific insertion (red). Asp334 is shown as 
sticks.
Figure 8 The DPP7 substrate-binding groove is occluded by the 
DPP7-specific structural insertion. Views of PRCP (top) and DPP7 
(bottom) showing the elongated, solvent-accessible substrate binding 
groove of PRCP (teal), and the binding site of DPP7 (teal) that is trun-
cated by the DPP7-specific insert (red).Soisson et al. BMC Structural Biology 2010, 10:16
http://www.biomedcentral.com/1472-6807/10/16
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[29]. Structure alignments were performed using SSM
[36] and DALI [37].
The PRCP coordinates have been deposited in the Pro-
tein Data Bank (PDB Code: 3N2Z)
Abbreviations
DPP4: dipeptidyl peptidase 4; DPP7: dipeptidyl peptidase 7; FOM: figure of
merit; MIRAS: multiple isomorphous replacement with anomalous scattering;
PEP: prolylendopeptidase; PRCP: prolylcarboxypeptidase; r.m.s.d.: root mean
square deviation.
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